A multicenter, prospective, observational study of patients receiving trastuzumab deruxtecan for the treatment of HER2-positive and HER2-low unresectable and/or metastatic breast cancer: DESTINY-Breast-RESPOND

被引：0
|
作者：
O'Shaughnessy, Joyce
Basho, Reva
Lustberg, Maryam
Lyman, Gary H.
Prahladan, Manoj
James, Gareth D.
Varghese, Della
Lujan, Flavia
Tesch, Hans
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-17-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-17-02
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Trastuzumab deruxtecan vs treatment of physician's choice in patients with HER2-low unresectable and/or metastatic breast cancer: Subgroup analyses from DESTINY-Breast04
    Harbeck, Nadia
    Modi, Shanu
    Jacot, William
    Yamashita, Toshinari
    Sohn, Joo Hyuk
    Vidal, Maria
    Tsurutani, Junji
    Ueno, Naoto T.
    Prat, Aleix
    Niikura, Naoki
    Xu, Binghe
    Rugo, Hope
    Papazisis, Konstantinos
    Cortes, Javier
    Krop, Ian
    Gambhire, Dhiraj
    Yung, Lotus
    Wang, Yibin
    Singh, Jasmeet
    Cameron, David
    CANCER RESEARCH, 2023, 83 (05)
  • [22] Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
    Jerusalem, Guy
    Park, Yeon Hee
    Yamashita, Toshinari
    Hurvitz, Sara A.
    Modi, Shanu
    Andre, Fabrice
    Krop, Ian E.
    Farre, Xavier Gonzalez
    You, Benoit
    Saura, Cristina
    Kim, Sung-Bae
    Osborne, Cynthia R.
    Murthy, Rashmi K.
    Gianni, Lorenzo
    Takano, Toshimi
    Liu, Yali
    Cathcart, Jillian
    Lee, Caleb
    Perrin, Christophe
    CANCER DISCOVERY, 2022, 12 (12) : 2754 - 2762
  • [23] Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
    Antonarelli, G.
    Corti, C.
    Salimbeni, B. T.
    Tarantino, P.
    Zagami, P.
    Marra, A.
    Trapani, D.
    Tolaney, S.
    Cortes, J.
    Curigliano, G.
    ESMO OPEN, 2023, 8 (04)
  • [24] The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment
    Wei, T.
    Wang, D.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2023, 34 (10) : 948 - 949
  • [25] The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer
    Schlam, Ilana
    Tolaney, Sara M.
    Tarantino, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (11) : 1059 - 1066
  • [26] Trastuzumab-Deruxtecan in the Therapy of HER2-positive Breast Cancer
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (06) : 365 - 365
  • [27] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
    Modi, Shanu
    Saura, Cristina
    Yamashita, Toshinari
    Park, Yeon Hee
    Kim, Sung-Bae
    Tamura, Kenji
    Andre, Fabrice
    Iwata, Hiroji
    Ito, Yoshinori
    Tsurutani, Junji
    Sohn, Joohyuk
    Denduluri, Neelima
    Perrin, Christophe
    Aogi, Kenjiro
    Tokunaga, Eriko
    Im, Seock-Ah
    Lee, Keun Seok
    Hurvitz, Sara A.
    Cortes, Javier
    Lee, Caleb
    Chen, Shuquan
    Zhang, Lin
    Shahidi, Javad
    Yver, Antoine
    Krop, Ian
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07) : 610 - 621
  • [28] Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study
    Modi, Shanu
    FUTURE ONCOLOGY, 2021, 17 (26) : 3415 - 3423
  • [29] Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
    Linehan, Anna S.
    Fitzpatrick, Orla M.
    Morris, Patrick G.
    BREAST CANCER-TARGETS AND THERAPY, 2021, 13 : 151 - 159
  • [30] Trastuzumab-Deruxtecan in the Therapy of HER2-positive Breast Cancer
    Schmale, Ine
    BREAST CARE, 2021, 16 (03)
12345